Herpes simplex meningitis Trials in Disease

Study on Aciclovir and Valaciclovir for Treating HSV-2 Meningitis in Adults

This clinical trial is being conducted in Denmark and focuses on finding better treatment options for adults with HSV-2 meningitis. The study compares two antiviral medications, Aciclovir and Valaciclovir, against a placebo to determine which approach is most effective in managing this viral infection.

Who can participate:

The trial is open to adults between 18 and 64 years old who have been diagnosed with viral meningitis. To be eligible, participants must have symptoms consistent with this condition, such as headache, stiff neck, sensitivity to light, or fever. They must also have an elevated white blood cell count in the cerebrospinal fluid (more than 4 cells per microliter) and test positive for HSV-2 using a PCR test. Additionally, participants need to be fully alert with a Glasgow Coma Scale score of 15 and be able to take oral medications.

Who cannot participate:

Individuals who have previously had HSV-2 meningitis are not eligible for this study. The trial also excludes people who belong to vulnerable populations, which includes groups who may have difficulty providing informed consent or who might be at higher risk of harm during the research.

What the trial involves:

The main goal of this study is to determine whether treatment with Aciclovir or Valaciclovir is more effective than a placebo in reducing symptoms of viral meningitis. Aciclovir works by preventing the virus from replicating, and it can be given either through a vein or taken orally. Valaciclovir is taken as a tablet and converts to Aciclovir in the body, making it easier to absorb.

Participants are randomly assigned to receive either the active medication or a placebo in a double-blinded manner, meaning neither the participant nor the researchers know which treatment is being given. Throughout the study, patients are closely monitored for symptom improvement, side effects, and overall quality of life. The primary measure of success is evaluated at 7 days after starting treatment, with additional follow-up assessments at 3 months and 12 months.

Investigational drugs:

The trial is testing two antiviral medications. Aciclovir is administered either through a vein as an infusion or taken orally, depending on the patient's condition. It works by blocking viral DNA replication, which helps stop the virus from spreading. Valaciclovir is taken as an oral tablet and is converted into Aciclovir once inside the body. This conversion process enhances absorption and effectiveness. Both medications belong to the antiviral class and are commonly used to treat herpes virus infections.